A novel pre clinical approach to evaluating tumor oxygen dynamics was recently introduced (Am. J. Clin. Oncol. 24, 462–466 (2001)). FREDOM (Fluorocarbon Relaxometry using Echo planar imaging for Dynamic Oxygen Mapping) allows maps of tumor pO2 including 50 – 150 individual locations simultaneously to be produced with typical in plane resolution of 1.25 mm in 6.5 mins. The technique has been applied extensively in rat prostate tumors and is now demonstrated in the rat breast 13762NF adenocarcinoma. When anesthetized rats breathed 33% oxygen, mean baseline pO2 was in the range 17 ± 2 (se) torr to 74 ± 4 torr with mean value for nine tumors 46 ± 8 torr. However, small tumors (< 2.2 cm3) were significantly better oxygenated with mean pO2 = 63 ± 7 torr than large tumors (> 2.4 cm3) with mean pO2 24 ± 5 torr (p< 0.002). Switching the inhaled gas to oxygen or carbogen produced a significant and rapid increase in mean pO2 for both small and larger tumors (p< 0.05). Given the increasing evidence that tumor oxygenation is related to therapeutic outcome, we believe this approach to measuring tumor oxygen dynamics can be of value in predicting response to therapy, evaluating adjuvant interventions designed to modulate response to therapy, and in providing “Prognostic Radiology”.
StoneH. B., BrownJ. M., PhillipsT., and SutherlandR. M.Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Radiat. Res.136, 422–434 (1993).
2.
HöckelM., SchlengerK., AralB., MitzeM., SchäfferU., and VaupelP.Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res.56, 4509–15 (1996).
3.
ZhaoD., ConstantinescuC., HahnE. W., and MasonR. P.Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int. J. Radiat. Oncol. Biol. Phys.53, 744–756 (2002).
4.
ZhaoZ., ConstantinescuA., HahnE. W., and MasonR. P.Tumor oxygen dynamics with respect to growth and respiratory challenge: Investigation of the Dunning prostate R3327-HI tumor. Radiat. Res.156, 510–520 (2001).
5.
GriffithsJ. R.The OxyLite: A fibre-optic oxygen sensor. Br. J. Radiol.72, 627–30 (1999).
6.
SwartzH. M., LiuK. J., GodaF., and WalczakT.India ink: A potential clinically applicable EPR oximetry probe. Magn. Reson. Med.31, 229–232 (1994).
7.
HeJ., BegheinN., CerokeP., ClarksonR. B., SwartzH. M., and GallezB.Development of biocompatible oxygen-permeable films holding paramagnetic carbon particles: Evaluation of their performance and stability in EPR oximetry. Magn. Reson. Med.46, 610–4 (2001).
8.
WilsonD. F.Oxygen dependent quenching of phosphorescence: A perspective. ErdmannW. and BruleyD. F. (eds.) In: Oxygen Transport to Tissue XIV, pp. 195–201. New York, Plenum, 1992.
9.
DolbierW. R.Jr., LiA. R., KochC. J., ShiueC. Y., and KachurA. V.[18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl. Radia. Isotop.54, 73–80 (2001).
10.
ChapmanJ. D., EngelhardtE. L., StobbeC. C., SchneiderR. F., and HanksG. E.Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol.46, 229–37 (1998).
11.
SostmanH. D., RockwellS., SylvaA. L., MadwedD., CoferG., CharlesH. C., Negro-VillarR., and MooreD.Evaluation of BA 1112 rhabdomyosarcoma oxygenation with microelectrodes, optical spectrometry, radiosensitivity, and MRS. Magn. Reson. Med.20, 253–267 (1991).
12.
VaupelP., KelleherD. K., and EngelT.Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour. Br. J. Cancer.69, 46–49 (1994).
13.
RobinsonS. P., CollingridgeD. R., HoweF. A., RodriguesL. M., ChaplinD. J., and GriffithsJ. R.Tumor response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed.12, 98–106 (1999).
14.
WangZ., SuM.-Y., and NalciogluO.Applications of Dynamic Contrast Enhanced MRI in Oncology: Measurement of Tumor Oxygen Tension. Technol. Cancer Res. Treat.1, 29–38 (2002).
15.
LyngH., VorrenA. O., SundforK., TaksdalI., LienH. H., KaalhusO., and RofstadE. K.Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. JMRI.14, 750–6 (2001).
16.
CooperR. A., CarringtonB. M., LoncastersJ. A., ToddS. M., DavidsonS. E., LogueJ. P., LuthraA. D., JonesA. P., StratfordI., HunterR. D., and WestC. M. L.Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother. Oncol.57, 53–59 (2000).
17.
ZhaoD., ConstantinescuA., JiangL., HahnE. W., and MasonR. P.Prognostic Radiology: Quantitative assessment of tumor oxygen dynamics by MRI. Am. J. Clin. Oncol.24, 462–466 (2001).
MasonR. P., RodbumrungW., and AntichP. P.Hexafluorobenzene: A sensitive 19F NMR indicator of tumor oxygenation. NMR in Biomed.9, 125–134 (1996).
20.
ThomasS. R., PrattR. G., MillardR. W., SamaratungaR. C., ShiferawY., ClarkL. C.Jr., and HoffmannR. E.Evaluation of the Influence of the Aqueous Phase Bioconstituent Environment on the F-19 T1 of Perfluorocarbon Blood Substitute Emulsions. JMRI.4, 631–635 (1994).
21.
MasonR. P., ShuklaH. P., and AntichP. P.In vivo oxygen tension and temperature: Simultaneous determination using 19F spectroscopy of perfluorocarbon. Magn. Reson. Med.29, 296–302 (1993).
22.
ThomasS. R.The biomedical applications of Fluorine-19 NMR. PartainC. L., PriceR. R., PattonJ. A., KulkarniM. V., and JamesA. E. J. (eds.), In: Magnetic Resonance Imaging, Vol. 2, pp. 1536–1552. London, W. B. Saunders Co., 1988.
23.
ZhaoD., ConstantinescuA., HahnE. W., and MasonR. P.Measurement of tumor oxygen dynamics predicts beneficial adjuvant intervention for radiotherapy in Dunning prostate R3327-HI tumors. Radiat. Res. accepted for publication (2002).
24.
HunjanS., ZhaoD., ConstantinescuA., HahnE. W., AntichP. P., and MasonR. P.Tumor Oximetry: Demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. Int. J. Radiat. Oncol. Biol. Phys.49, 1097–1108 (2001).
25.
BogdenA. E., KeltonD. E., CobbW. R., GulkinT. A., and JohsonR. K.Effect of serial passage in nude athymic mice on the growth characteristics and chemotherapy responsiveness of 13762 and R3230AC mammary tumor xenografts. Cancer Res.38, 59–63 (1978).
26.
HahnE. W., PeschkeP., MasonR. P., BabcockE. E., and AntichP. P.Isolated tumor growth in a surgically formed skin pedicle in the rat: A new tumor model for NMR studies. Magn. Reson. Imaging.11, 1007–1017 (1993).
27.
BarkerB. R., MasonR. P., BansalN., and PeshockR. M.Oxygen tension mapping by 19F echo planar NMR imaging of sequestered perfluorocarbon. JMRI.4, 595–602 (1994).
28.
VaupelP. W., FortmeyerH. P., RunkelS., and KallinowskiF.Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res.47, 3496–503 (1987).
29.
RofstadE., DeMuthP., FentonB., and SutherlandR.31P NMR spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia. Cancer Res.48, 5440–5446 (1988).
30.
FylesA. W., MilosevicM., WongR., KavanaghM.-C., PintileM., SunA., ChapmanW., LevinW., ManchulL., KeaneT. J., and HillR. P.Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol.48, 149–56 (1998).
31.
LartigauE., Le RidantA. M., LambinP., WeegerP., MartinL., SigalR., LusinchiA., LuboinskiB., EschwegeF., and GuichardM.Oxygenation of head and neck tumors. Cancer.71, 2319–25 (1993).
32.
HohenbergerP., FelgerC., HaenschW., and SchlagP. M.Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res. Treatment.48, 97–106 (1998).
33.
VaupelP. and HockelM.Oxygenation status of breast cancer: The Mainz experience. VaupelP. and KelleherD. K. (eds.) In: Tumor Hypoxia, pp. 1–11. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1999.
34.
RudatV., VanselowB., WollensackP., BettscheiderC., Osman-AhmetS., EbleM. J., and DietzA.Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother. Oncol.57, 31–37 (2000).
35.
NordsmarkM. and OvergardJ.Oxygenation of human tumors: The Aarhus experience. VaupelP. and KelleherD. K. (eds.). In: Tumor Hypoxia, pp. 19–27. Stuttgart, Wissenschaftliche Verlagsgesellschaft, 1999.
36.
DardzinskiB. J. and SotakC. H.Rapid tissue oxygen tension mapping using 19F Inversion-recovery Echo-planar imaging of Perfluoro-15-crown-5-ether. Magn. Reson. Med.32, 88–97 (1994).
37.
MasonR. P. and AntichP. P.Tumor oxygen tension: Measurement using OxygentTM as a 19F NMR probe at 4.7 T.Artif. Cells Blood Subst. Immob. Biotechnol.22, 1361–1367 (1994).
38.
MasonR. P., AntichP. P., BabcockE. E., ConstantinescuA., PeschkeP., and HahnE. W.Non-invasive determination of tumor oxygen tension and local variation with growth. Int. J. Radiat. Oncol. Biol. Phys.29, 95–103 (1994).
39.
CourtneyK. D. and AndrewsJ. E.Teratogenic evaluation and fetal deposition of hexabromobenzene (HBB) and hexafluorobenzene (HFB) in CD-1 mice. J. Environ. Sci. Health B.19, 83–94 (1984).
40.
GrosmanY. S. and KapitonenkoT. A.Pharmacology and toxicology of hexafluorobenzene. Izv. Estestvennonauchu. Inst. Pevinsk.15, 155–63 (1973).
41.
HallL. W., JacksonS. R. K., and MasseyG. M.Hexafluorobenzene in veterinary anaesthesia. AriasA., LlauradoR., NaldaM. A., and LunnJ. N., (eds.), In: Recent Progress in Anaesthesiology and Resuscitation, pp. 201–204. Oxford, Excerpta Medica, 1975.
42.
HunjanS., MasonR. P., ConstantinescuA., PeschkeP., HahnE. W., and AntichP. P.Regional tumor oximetry: 19F NMR spectroscopy of hexafluorobenzene. Int. J. Radiat. Oncol. Biol. Phys.40, 161–71 (1998).
43.
LiuH., SongY., WordenK. L., JiangX., ConstantinescuA., and MasonR. P.Noninvasive Investigation of Blood Oxygenation Dynamics of Tumors by Near-Infrared Spectroscopy. Appl. Optic.39, 5231–43 (2000).
44.
HoweF. A., RobinsonS. P., RodriguesL. M., and GriffithsJ. R.Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn. Reson. Imaging.17, 1307–18 (1999).
45.
KnoppM. V., WeissE., SinnH. P., MatternJ., JunkermannH., RadeleffJ., MagenerA., BrixG., DelormeS., ZunaI., and van KaickG.Pathophysiologic basis of contrast enhancement in breast tumors. J. Magn. Reson. Imaging.10, 260–6 (1999).
46.
BarentszJ. O., EngelbrechtM., JagerG. J., WitjesJ. A., de LaRosetteJ., van Der SandenB. P., HuismanH. J., and HeerschapA.Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. [Review]. JMRI.10, 295–304 (1999).
47.
GulledgeC. J. and DewhirstM. W.Tumor oxygenation: A matter of supply and demand. Anticancer Res.16, 741–9 (1996).
48.
ZhongH., AganiF., BaccalaA. A., LaughnerE., Rioseco-CamachoN., IsaacsW. B., SimonsJ. W., and SemenzaG. L.Increased expression of hypoxia induciblefactor-1alpha in rat and human prostate cancer. Cancer Res.58, 5280–4 (1998).
49.
HaensgenG., KrauseU., BeckerA., StadlerP., LautenschlaegerC., WohlrabW., RathF. W., MollsM., and DunstJ.Tumor hypoxia, p53, and prognosis in cervical cancers. Int. J. Radiat. Oncol., Biol. Phys.50, 865–72 (2001).
50.
MaruyamaR., ToyookaS., ToyookaK. O., VirmaniA. K., Zochbauer-MullerS., FarinasA. J., MinnaJ. D., McConnellJ., FrenkelE. P., and GazdarA. F.Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clinic. Cancer Res.8, 514–9 (2002).
51.
MasonR. P., RanS., ThorpeP. E., Quantitative Assessment of Tumor Oxygen Dynamics: Molecular Imaging for Prognostic Radiology, J. Cell. Biochem. In press 2003.
52.
ZhaoD., ConstantinescuA., ChangK. C., GallK., HahnE. W., and MasonR. P.Measurement of tumor oxygen dynamics correctly predicts beneficial adjuvant intervention for radiotherapy in Dunning prostate R3327-HI tumors. In: ISMRM 10th Scientific Meeting, Honolulu, Hawaii, USA, 2002, pp. 2149.
